You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Jak

Showing 26 - 50 of 686
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rheumatoid Arthritis Patients Treated With JAK-inhibitor

Recruiting
  • Rheumatoid Arthritis
  • Upadacitinib <15 MG [Rinvoq]
  • Montpellier, France
    CHU de Montpellier
Jan 12, 2022

Sarcoidosis Trial in New Haven (Abrocitinib 200 mg)

Not yet recruiting
  • Sarcoidosis
  • Abrocitinib 200 mg
  • New Haven, Connecticut
    Yale University
Jan 24, 2023

JAK Inhibitors in Systemic Sclerosis-associated Interstitial

Recruiting
  • Systemic Sclerosis
  • Interstitial Lung Disease
    • Vandœuvre-lès-Nancy, Grand Est, France
      CHU Nancy
    Jan 19, 2022

    Rheumatoid Arthritis, Drug Use Trial in Hong Kong (biologic/targeted therapy)

    Not yet recruiting
    • Rheumatoid Arthritis
    • Drug Use
    • biologic/targeted therapy
    • Hong Kong, China
      Department of Medicine, Tuen Mun Hospital
    Jan 5, 2022

    Rheumatoid Arthritis Trial in Montpellier (Blood sample analysis of patients treated as standard care)

    Recruiting
    • Rheumatoid Arthritis
    • Blood sample analysis of patients treated as standard care
    • Montpellier, France
      University Hospital of Montpellier
    Jan 12, 2022

    Polycythemia Vera Trial (Givinostat Hydrochloride, Hydroxy Urea)

    Not yet recruiting
    • Polycythemia Vera
    • Givinostat Hydrochloride
    • Hydroxy Urea
    • (no location specified)
    Oct 19, 2023

    Lupus Nephritis Trial in Assiut (Anti JAK1,2)

    Active, not recruiting
    • Lupus Nephritis
    • Anti JAK1,2
    • Assiut, Assuit, Egypt
      Manal Hassanien
    Jun 21, 2022

    Granuloma Annulare Trial in New Haven (Abrocitinib 200 mg)

    Not yet recruiting
    • Granuloma Annulare
    • Abrocitinib 200 mg
    • New Haven, Connecticut
      Yale University
    Dec 19, 2022

    Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor Trial in Nagasaki (filgotinib 200mg/day, subcutaneous tocilizumab

    Recruiting
    • Rheumatoid Arthritis
    • +4 more
    • filgotinib 200mg/day
    • subcutaneous tocilizumab 162mg/biweekly
    • Nagasaki, Japan
      Nagasaki University Hospital
    Oct 23, 2021

    Myeloproliferative Tumor, Essential Thrombocythemia, JAK2 Mutation Trial in Ottawa (Apixaban 2.5 MG Oral Tablet [ELIQUIS],

    Recruiting
    • Myeloproliferative Neoplasm
    • +5 more
    • Apixaban 2.5 MG Oral Tablet [ELIQUIS]
    • Aspirin 81 mg
    • Ottawa, Ontario, Canada
      The Ottawa Hospital
    Apr 19, 2022

    Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)

    Active, not recruiting
    • Primary Myelofibrosis
    • Secondary Myelofibrosis
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +11 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 10, 2023

    Graft Vs Host Disease, Graft-versus-host-disease, GVHD Trial in Saint Louis (Ruxolitinib)

    Not yet recruiting
    • Graft Vs Host Disease
    • +2 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Aug 18, 2023

    Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

    Recruiting
    • Arthritis, Rheumatoid
      • Sevilla, Spain
        Hospital Universitario Virgen macarena
      Nov 15, 2021

      Primary Myelofibrosis, Secondary Myelofibrosis Trial in Greifswald, Halle (Saale) (Fedratinib Oral Capsule [Inrebic], Nivolumab)

      Recruiting
      • Primary Myelofibrosis
      • Secondary Myelofibrosis
      • Greifswald, Germany
      • +1 more
      Jun 15, 2022

      Immunoclassification, Psoriasis Trial in Hangzhou (adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors,

      Recruiting
      • Immunoclassification
      • Psoriasis
      • adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
      • Hangzhou, Zhejiang, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Aug 16, 2022

      COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors Trial

      Withdrawn
      • COVID 19
      • Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
      • (no location specified)
      Sep 8, 2021

      Cicatricial Alopecia Trial in New York (PF-06651600)

      Not yet recruiting
      • Cicatricial Alopecia
      • New York, New York
        Icahn School of Medicine at Mount Sinai
      Sep 19, 2022

      Dermatomyositis, Adult Type Trial in Xi'an (JAK Inhibitor)

      Recruiting
      • Dermatomyositis, Adult Type
      • JAK Inhibitor
      • Xi'an, Shaanxi, China
        Department of Rheumatology, the First Affiliated Hospital of Xi'
      Jul 15, 2021

      Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)

      Not yet recruiting
      • Vitiligo
      • Effect of Drug
      • JAK-2 inhibitor
      • Topical corticosteroid
      • (no location specified)
      Mar 19, 2022

      Rheumatoid Arthritis Trial (Upadacitinib, Adalimumab)

      Not yet recruiting
      • Rheumatoid Arthritis
      • (no location specified)
      Nov 29, 2021

      Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

      Recruiting
      • Acute Myeloid Leukemia
      • +8 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Aug 18, 2022

      Bronchiolitis Obliterans Trial in Houston (Itacitinib, Itacitinib Adipate)

      Recruiting
      • Bronchiolitis Obliterans
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 24, 2023

      Inpatient COVID-19 Treatments

      Active, not recruiting
      • COVID-19
      • Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
      • New York, New York
        Aetion, Inc.
      Jan 12, 2023

      Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))

      Recruiting
      • Advanced Hepatocellular Carcinoma
      • Itacitinib (INCB039110)
      • London, United Kingdom
        Imperial College Healthcare NHS Trust
      Jul 14, 2022

      T-Cell Large Granular Lymphocyte Leukemia Trial in Columbus (Ruxolitinib)

      Not yet recruiting
      • T-Cell Large Granular Lymphocyte Leukemia
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Oct 20, 2022